Sundén-Cullberg Jonas, Nyström Thomas, Lee Martin L, Mullins Gail E, Tokics Leif, Andersson Jan, Norrby-Teglund Anna, Treutiger Carl Johan
Department of Medicine, Division of Infectious Diseases, Center for Infectious Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden.
Crit Care Med. 2007 Jun;35(6):1536-42. doi: 10.1097/01.CCM.0000266536.14736.03.
Resistin induces insulin resistance in mice. In humans, recent data suggest that resistin functions as a proinflammatory cytokine. Here, we studied resistin up to 2 wks after admission in patients with septic shock and/or severe sepsis.
Two prospective studies of patients with sepsis and in vitro studies of resistin interaction with monocytes.
Intensive care unit at Karolinska University Hospital and Center for Infectious Medicine, Karolinska Institute, Huddinge, Sweden.
Twenty-nine patients with severe sepsis and 66 with septic shock.
None.
Ninety-five patients were studied, 25 of whom died within 28 days. Resistin and cytokine levels and routine biochemistry were measured at three to six defined time points during the first 2 wks after admission and were correlated to other cytokines, glucose levels, body mass index, Acute Physiology and Chronic Health Evaluation II, and Sepsis-related Organ Failure Assessment scores. Serum resistin was significantly elevated compared with healthy controls (p < .000001) and correlated with severity of disease as measured by Acute Physiology and Chronic Health Evaluation II and Sepsis-related Organ Failure Assessment scores, with an increasingly strong degree of correlation over time. Median levels were four- to eight-fold higher than controls and remained high up to 2 wks after admission to the intensive care unit. Levels correlated with interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-alpha, creatinine, D-dimer, and lactate, but not with p-glucose or body mass index. In vitro, resistin was released from monocytes after stimulation with either lipopolysaccharide or high mobility group box 1 protein. Recombinant resistin itself up-regulated intercellular adhesion molecule-1 on monocytes.
This is the first study assessing systemic levels of resistin in patients with septic shock/severe sepsis. We show that resistin is a marker of severity of disease and possibly a mediator of the prolonged inflammatory state seen in infected critically ill patients. Further exploration of resistin as a therapeutic target and marker of disease is merited.
抵抗素可诱导小鼠产生胰岛素抵抗。在人类中,近期数据表明抵抗素作为一种促炎细胞因子发挥作用。在此,我们对脓毒性休克和/或严重脓毒症患者入院后长达2周的抵抗素情况进行了研究。
两项关于脓毒症患者的前瞻性研究以及抵抗素与单核细胞相互作用的体外研究。
瑞典胡丁厄市卡罗林斯卡大学医院重症监护病房及卡罗林斯卡学院传染病中心。
29例严重脓毒症患者和66例脓毒性休克患者。
无。
共研究了95例患者,其中25例在28天内死亡。在入院后的前2周内,于三个至六个特定时间点测量抵抗素、细胞因子水平及常规生化指标,并将其与其他细胞因子、血糖水平、体重指数、急性生理与慢性健康状况评分系统II(APACHE II)以及脓毒症相关器官功能衰竭评估(SOFA)评分进行关联分析。与健康对照相比,血清抵抗素显著升高(p <.000001),并且与通过APACHE II和SOFA评分所衡量的疾病严重程度相关,随着时间推移相关性越来越强。中位数水平比对照高四至八倍,在入住重症监护病房后长达2周仍保持较高水平。其水平与白细胞介素-6、白细胞介素-8、白细胞介素-10、肿瘤坏死因子-α、肌酐、D-二聚体和乳酸相关,但与血糖或体重指数无关。在体外,脂多糖或高迁移率族蛋白B1刺激单核细胞后可释放抵抗素。重组抵抗素本身可上调单核细胞上的细胞间黏附分子-1。
这是第一项评估脓毒性休克/严重脓毒症患者体内抵抗素全身水平的研究。我们表明抵抗素是疾病严重程度的标志物,并且可能是感染的危重症患者中持续炎症状态的介质。值得进一步探索将抵抗素作为治疗靶点和疾病标志物。